ES2760263T3 - Tratamiento génico de la retinitis pigmentaria - Google Patents
Tratamiento génico de la retinitis pigmentaria Download PDFInfo
- Publication number
- ES2760263T3 ES2760263T3 ES15716232T ES15716232T ES2760263T3 ES 2760263 T3 ES2760263 T3 ES 2760263T3 ES 15716232 T ES15716232 T ES 15716232T ES 15716232 T ES15716232 T ES 15716232T ES 2760263 T3 ES2760263 T3 ES 2760263T3
- Authority
- ES
- Spain
- Prior art keywords
- mir
- rhodopsin
- nucleic acid
- seq
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007014 Retinitis pigmentosa Diseases 0.000 title claims description 122
- 108090000623 proteins and genes Proteins 0.000 title description 75
- 238000011282 treatment Methods 0.000 title description 41
- 108091089534 miR-708 stem-loop Proteins 0.000 claims abstract description 483
- 108090000820 Rhodopsin Proteins 0.000 claims abstract description 350
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims abstract description 309
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 296
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 280
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 280
- 239000002245 particle Substances 0.000 claims abstract description 210
- 102000004330 Rhodopsin Human genes 0.000 claims abstract 13
- 210000004027 cell Anatomy 0.000 claims description 171
- 239000013598 vector Substances 0.000 claims description 151
- 241000700605 Viruses Species 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 94
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 76
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 71
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 70
- 108050001704 Opsin Proteins 0.000 claims description 68
- 102000010175 Opsin Human genes 0.000 claims description 67
- 210000000234 capsid Anatomy 0.000 claims description 60
- 239000013608 rAAV vector Substances 0.000 claims description 57
- 241000124008 Mammalia Species 0.000 claims description 54
- 238000012217 deletion Methods 0.000 claims description 52
- 230000037430 deletion Effects 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 42
- 230000035772 mutation Effects 0.000 claims description 36
- 102000040430 polynucleotide Human genes 0.000 claims description 36
- 108091033319 polynucleotide Proteins 0.000 claims description 36
- 239000002157 polynucleotide Substances 0.000 claims description 36
- 210000001525 retina Anatomy 0.000 claims description 35
- 150000001413 amino acids Chemical group 0.000 claims description 34
- 230000003612 virological effect Effects 0.000 claims description 34
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 claims description 31
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 27
- 108091033773 MiR-155 Proteins 0.000 claims description 25
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 21
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 15
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 15
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 15
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 15
- 241000702421 Dependoparvovirus Species 0.000 claims description 15
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 14
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 13
- 241000283707 Capra Species 0.000 claims description 12
- 239000013646 rAAV2 vector Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 210000003660 reticulum Anatomy 0.000 claims 2
- 102100040756 Rhodopsin Human genes 0.000 description 318
- 230000014509 gene expression Effects 0.000 description 146
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 73
- 108090000799 Rhodopsin kinases Proteins 0.000 description 73
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 description 72
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 description 60
- 241000699666 Mus <mouse, genus> Species 0.000 description 55
- 230000035882 stress Effects 0.000 description 54
- 239000013607 AAV vector Substances 0.000 description 53
- 241000282414 Homo sapiens Species 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 34
- 108091036066 Three prime untranslated region Proteins 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 31
- 241000701022 Cytomegalovirus Species 0.000 description 27
- 102000040945 Transcription factor Human genes 0.000 description 25
- 108091023040 Transcription factor Proteins 0.000 description 25
- 239000003623 enhancer Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 108091008038 CHOP Proteins 0.000 description 20
- 102100021246 DDIT3 upstream open reading frame protein Human genes 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 210000005157 neural retina Anatomy 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000030833 cell death Effects 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 101000586066 Mus musculus Rhodopsin Proteins 0.000 description 15
- 108091008695 photoreceptors Proteins 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- 108091070501 miRNA Proteins 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 108090000565 Capsid Proteins Proteins 0.000 description 11
- 102100023321 Ceruloplasmin Human genes 0.000 description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000002679 microRNA Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 201000004569 Blindness Diseases 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000002207 retinal effect Effects 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 6
- 201000007737 Retinal degeneration Diseases 0.000 description 6
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000004258 retinal degeneration Effects 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 101150112743 HSPA5 gene Proteins 0.000 description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 5
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 5
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 5
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 4
- 101000597428 Homo sapiens Nucleoredoxin-like protein 1 Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 101000597433 Mus musculus Nucleoredoxin-like protein 1 Proteins 0.000 description 4
- 102100035399 Nucleoredoxin-like protein 1 Human genes 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000004296 scotopic vision Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000717377 Homo sapiens Ribokinase Proteins 0.000 description 3
- 208000001140 Night Blindness Diseases 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004297 night vision Effects 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000005043 peripheral vision Effects 0.000 description 3
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 101150017921 DDIT3 gene Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 2
- 101000661555 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L22-A Proteins 0.000 description 2
- 101000661557 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L22-B Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108091027943 miR-16 stem-loop Proteins 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 101150079354 rho gene Proteins 0.000 description 2
- -1 rhodopsin nucleic acid Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102000000132 Alpha tubulin Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100476827 Bacillus subtilis (strain 168) scoA gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000968229 Homo sapiens DDIT3 upstream open reading frame protein Proteins 0.000 description 1
- 101000918631 Homo sapiens DNA damage-inducible transcript 3 protein Proteins 0.000 description 1
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001096050 Homo sapiens Perilipin-2 Proteins 0.000 description 1
- 101000666331 Homo sapiens Teneurin-4 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102220515784 Nuclear receptor subfamily 0 group B member 2_N15K_mutation Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101710131038 Opsin-2 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000008710 congenital stationary night blindness autosomal dominant 1 Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000055172 human DDIT3 Human genes 0.000 description 1
- 102000051914 human PLIN2 Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091042687 miR-1555 stem-loop Proteins 0.000 description 1
- 108091047568 miR-7083 stem-loop Proteins 0.000 description 1
- 108091028267 miR-7085 stem-loop Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008298 phosphoramidates Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200141522 rs28933394 Human genes 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969027P | 2014-03-21 | 2014-03-21 | |
| PCT/US2015/021896 WO2015143418A2 (en) | 2014-03-21 | 2015-03-20 | Gene therapy for retinitis pigmentosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2760263T3 true ES2760263T3 (es) | 2020-05-13 |
Family
ID=52829343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15716232T Active ES2760263T3 (es) | 2014-03-21 | 2015-03-20 | Tratamiento génico de la retinitis pigmentaria |
| ES19186929T Active ES2957840T3 (es) | 2014-03-21 | 2015-03-20 | Tratamiento génico de la retinitis pigmentaria |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19186929T Active ES2957840T3 (es) | 2014-03-21 | 2015-03-20 | Tratamiento génico de la retinitis pigmentaria |
Country Status (36)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2760263T3 (es) * | 2014-03-21 | 2020-05-13 | Genzyme Corp | Tratamiento génico de la retinitis pigmentaria |
| US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
| US10994026B2 (en) | 2015-12-03 | 2021-05-04 | Friedrich Miescher Institute For Biomedical Research | SynP160, a promoter for the specific expression of genes in rod photoreceptors |
| WO2017093936A1 (en) | 2015-12-03 | 2017-06-08 | Friedrich Miescher Institute For Biomedical Research | Synp162, a promoter for the specific expression of genes in rod photoreceptors |
| US11390866B2 (en) | 2015-12-04 | 2022-07-19 | Sorbonne Université | Promoters and uses thereof |
| IL261014B2 (en) * | 2016-03-01 | 2023-10-01 | Univ Florida | Aav vectors for treatment of dominant retinitis pigmentosa |
| MX2019000262A (es) * | 2016-07-05 | 2019-05-27 | Univ Johns Hopkins | Composiciones basadas en crispr/cas9 y metodos para el tratamiento de degeneraciones retinianas. |
| WO2018172961A1 (en) * | 2017-03-21 | 2018-09-27 | Ludwig-Maximilians-Universität München | Gene therapy for the treatment of cngb1-linked retinitis pigmentosa |
| EP3684932A1 (en) * | 2017-09-22 | 2020-07-29 | Genzyme Corporation | Variant rnai |
| US20200263196A1 (en) * | 2017-09-27 | 2020-08-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising active cells |
| CN107961380B (zh) * | 2017-11-23 | 2020-05-05 | 清华大学 | 试剂在制备药物中的用途、筛选药物的方法以及药物组合物 |
| US12162994B2 (en) | 2018-03-02 | 2024-12-10 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| US20210017509A1 (en) * | 2018-03-23 | 2021-01-21 | The Trustees Of Columbia University In The City Of New York | Gene Editing for Autosomal Dominant Diseases |
| TW202014181A (zh) | 2018-04-04 | 2020-04-16 | 美商希吉隆醫療公司 | 可植入顆粒及相關方法 |
| JP7563694B2 (ja) | 2018-06-01 | 2024-10-08 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 優性網膜色素変性症の処置のための組成物および方法 |
| GB201817469D0 (en) * | 2018-10-26 | 2018-12-12 | Univ Oxford Innovation Ltd | Gene therapy for retinal disease |
| CN111518813B (zh) * | 2019-02-03 | 2023-04-28 | 武汉纽福斯生物科技有限公司 | 视紫红质的编码序列、其表达载体构建及其应用 |
| US20220143217A1 (en) * | 2019-03-04 | 2022-05-12 | The Trustees Of The University Of Pennsylvania | Neuroprotective gene therapy targeting the akt pathway |
| CN114206393A (zh) * | 2019-03-21 | 2022-03-18 | Ptc医疗公司 | 用于治疗天使综合征的载体和方法 |
| WO2021030745A1 (en) * | 2019-08-15 | 2021-02-18 | The Children's Hospital Of Philadelphia | Combined transgene and intron-derived mirna therapy for treatment of sca1 |
| EP4087617A4 (en) * | 2020-01-10 | 2024-05-01 | Solid Biosciences Inc. | VIRAL VECTOR FOR COMBINATION THERAPY |
| AU2021213786A1 (en) * | 2020-01-29 | 2022-09-22 | Genzyme Corporation | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
| KR102396200B1 (ko) * | 2020-07-24 | 2022-05-12 | 알지노믹스 주식회사 | 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도 |
| US20220331241A1 (en) * | 2021-04-16 | 2022-10-20 | Regeneron Pharmaceuticals, Inc. | Treatment of x-linked juvenile retinoschisis |
| TWI832531B (zh) * | 2022-11-02 | 2024-02-11 | 慈濟學校財團法人慈濟大學 | Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途 |
| CN117625619B (zh) * | 2023-12-05 | 2024-11-12 | 云舟生物科技(广州)股份有限公司 | 核酸分子及其作为特异启动子的应用 |
| CN120230798A (zh) * | 2023-12-29 | 2025-07-01 | 上海朗昇生物科技有限公司 | 用于视网膜基因递送的重组腺相关病毒载体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262529A (en) * | 1990-01-24 | 1993-11-16 | President And Fellows Of Harvard College | Diagnosis of hereditary retinal degenerative diseases |
| US5985583A (en) * | 1992-06-23 | 1999-11-16 | Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of gonadotropin-releasing hormone receptor |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| CA2915124C (en) | 2001-11-13 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| EP2434020B1 (en) * | 2004-01-22 | 2014-11-05 | Dnavec Research Inc. | Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| EP2140004B1 (en) * | 2007-04-12 | 2022-01-12 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Genetic suppression and replacement |
| US20090214478A1 (en) * | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US8734809B2 (en) * | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2475372B2 (en) * | 2009-09-10 | 2020-10-21 | Velin-Pharma A/S | Method for the preparation of micro-rna and its therapeutic application |
| PT2529020T (pt) | 2010-01-28 | 2018-07-30 | Childrens Hospital Philadelphia | Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN107828820B (zh) * | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
| JP6224459B2 (ja) | 2011-02-17 | 2017-11-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法 |
| JP5884152B2 (ja) | 2011-07-29 | 2016-03-15 | シャープ株式会社 | 基地局、端末、通信システムおよび通信方法 |
| ITRM20110685A1 (it) * | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
| BR112014020325A2 (pt) * | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| FI3597749T3 (fi) * | 2012-05-25 | 2023-10-09 | Univ California | Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten |
| CA2878171C (en) * | 2012-07-11 | 2021-04-27 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| CA2889020A1 (en) * | 2012-10-23 | 2014-05-01 | Cornell University | Treatment of metastatic breast cancer |
| TW201605470A (zh) | 2013-10-04 | 2016-02-16 | 默沙東藥廠 | 葡萄糖反應性胰島素結合物 |
| ES2760263T3 (es) | 2014-03-21 | 2020-05-13 | Genzyme Corp | Tratamiento génico de la retinitis pigmentaria |
-
2015
- 2015-03-20 ES ES15716232T patent/ES2760263T3/es active Active
- 2015-03-20 RS RS20230833A patent/RS64611B1/sr unknown
- 2015-03-20 HU HUE15716232A patent/HUE046454T2/hu unknown
- 2015-03-20 CA CA2943185A patent/CA2943185C/en active Active
- 2015-03-20 DK DK15716232T patent/DK3119437T3/da active
- 2015-03-20 NZ NZ724622A patent/NZ724622A/en unknown
- 2015-03-20 EA EA201691891A patent/EA201691891A1/ru unknown
- 2015-03-20 LT LTEP15716232.2T patent/LT3119437T/lt unknown
- 2015-03-20 LT LTEP19186929.6T patent/LT3628334T/lt unknown
- 2015-03-20 PE PE2016001643A patent/PE20161252A1/es unknown
- 2015-03-20 SG SG11201607005UA patent/SG11201607005UA/en unknown
- 2015-03-20 MY MYPI2016703077A patent/MY190726A/en unknown
- 2015-03-20 DK DK19186929.6T patent/DK3628334T5/da active
- 2015-03-20 FI FIEP19186929.6T patent/FI3628334T3/fi active
- 2015-03-20 SI SI201531019T patent/SI3119437T1/sl unknown
- 2015-03-20 EP EP19186929.6A patent/EP3628334B1/en active Active
- 2015-03-20 MX MX2016012201A patent/MX376190B/es active IP Right Grant
- 2015-03-20 ES ES19186929T patent/ES2957840T3/es active Active
- 2015-03-20 PT PT157162322T patent/PT3119437T/pt unknown
- 2015-03-20 PL PL15716232T patent/PL3119437T3/pl unknown
- 2015-03-20 EP EP23176679.1A patent/EP4345165A3/en active Pending
- 2015-03-20 PL PL19186929.6T patent/PL3628334T3/pl unknown
- 2015-03-20 HR HRP20192141TT patent/HRP20192141T1/hr unknown
- 2015-03-20 CN CN202210690697.4A patent/CN115252823A/zh active Pending
- 2015-03-20 HR HRP20231077TT patent/HRP20231077T1/hr unknown
- 2015-03-20 AU AU2015230942A patent/AU2015230942B2/en active Active
- 2015-03-20 US US15/127,757 patent/US10383953B2/en active Active
- 2015-03-20 PT PT191869296T patent/PT3628334T/pt unknown
- 2015-03-20 WO PCT/US2015/021896 patent/WO2015143418A2/en not_active Ceased
- 2015-03-20 KR KR1020227045369A patent/KR20230006039A/ko not_active Ceased
- 2015-03-20 HU HUE19186929A patent/HUE063460T2/hu unknown
- 2015-03-20 RS RS20191551A patent/RS59634B1/sr unknown
- 2015-03-20 CN CN201580026274.0A patent/CN106456660B/zh active Active
- 2015-03-20 CA CA3254798A patent/CA3254798A1/en active Pending
- 2015-03-20 JP JP2016557218A patent/JP6669664B2/ja active Active
- 2015-03-20 SI SI201531966T patent/SI3628334T1/sl unknown
- 2015-03-20 SG SG10201912968WA patent/SG10201912968WA/en unknown
- 2015-03-20 SG SG10201808218YA patent/SG10201808218YA/en unknown
- 2015-03-20 MY MYPI2020002274A patent/MY203654A/en unknown
- 2015-03-20 CR CR20160480A patent/CR20160480A/es unknown
- 2015-03-20 EP EP15716232.2A patent/EP3119437B1/en active Active
- 2015-03-20 UA UAA201610589A patent/UA120050C2/uk unknown
- 2015-03-20 KR KR1020167028893A patent/KR20160127832A/ko not_active Ceased
- 2015-03-20 MA MA39390A patent/MA39390B2/fr unknown
- 2015-03-23 TW TW109103078A patent/TWI780401B/zh active
- 2015-03-23 UY UY0001036044A patent/UY36044A/es not_active Application Discontinuation
- 2015-03-23 TW TW104109152A patent/TWI706789B/zh active
- 2015-03-25 AR ARP150100879A patent/AR099837A1/es active IP Right Grant
-
2016
- 2016-08-24 PH PH1/2016/501684A patent/PH12016501684B1/en unknown
- 2016-08-25 ZA ZA2016/05924A patent/ZA201605924B/en unknown
- 2016-08-30 IL IL247543A patent/IL247543B/en active IP Right Grant
- 2016-09-09 DO DO2016000237A patent/DOP2016000237A/es unknown
- 2016-09-15 CL CL2016002333A patent/CL2016002333A1/es unknown
- 2016-09-20 MX MX2020010694A patent/MX2020010694A/es unknown
- 2016-10-21 EC ECIEPI201683000A patent/ECSP16083000A/es unknown
-
2019
- 2019-07-03 US US16/503,091 patent/US11103598B2/en active Active
- 2019-12-12 JP JP2019224202A patent/JP7048563B2/ja active Active
-
2020
- 2020-07-08 IL IL275918A patent/IL275918B/en unknown
-
2021
- 2021-02-15 AU AU2021200988A patent/AU2021200988B2/en active Active
- 2021-07-11 IL IL284741A patent/IL284741B2/en unknown
- 2021-07-22 US US17/383,052 patent/US12201698B2/en active Active
-
2022
- 2022-03-23 JP JP2022046280A patent/JP7534348B2/ja active Active
-
2024
- 2024-10-30 AU AU2024227776A patent/AU2024227776A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2760263T3 (es) | Tratamiento génico de la retinitis pigmentaria | |
| US20240197837A1 (en) | Gene editing of deep intronic mutations | |
| JP2020535803A (ja) | バリアントＲＮＡｉ | |
| HK40109446A (en) | Gene therapy for retinitis pigmentosa | |
| HK40080889A (en) | Gene therapy for retinitis pigmentosa | |
| HK40026944B (en) | Gene therapy for retinitis pigmentosa | |
| HK40026944A (en) | Gene therapy for retinitis pigmentosa | |
| BR112016021017B1 (pt) | Partículas de raav, composições e uso das mesmas no tratamento para retinite pigmentosa ou no tratamento do estresse do retículo endoplasmático | |
| HK1233535A1 (en) | Gene therapy for retinitis pigmentosa | |
| HK1233535B (en) | Gene therapy for retinitis pigmentosa |